AI Insight
Many patients with type 2 diabetes remain inadequately controlled despite treatment with basal insulin, putting them at risk for serious vascular complications. Traditional treatment intensification through complex insulin regimens often leads to problematic side effects including hypoglycemia and weight gain. This highlights an urgent clinical need for alternative therapeutic approaches that can improve blood sugar control in patients who do not respond adequately to basal insulin alone.
Why it matters
The inadequate control of type 2 diabetes in a large proportion of insulin-treated patients represents a significant gap in current treatment strategies. New therapeutic options beyond insulin escalation could reduce serious complications while avoiding weight gain and dangerous drops in blood sugar levels that limit current treatment approaches.
A large proportion of people living with type 2 diabetes treated with basal insulin therapy remain inadequately controlled despite progressive treatment intensification,1 leaving many susceptible to microvascular and macrovascular complications.2 Treatment intensification has traditionally focused on complex insulin regimens, with hypoglycaemia and weight gain as undesirable adverse effects. Thus, the need for therapies that improve glycaemic control in people inadequately controlled on basal insulin therapy remains pressing.
Source: [Comment] Beyond insulin escalation: REIMAGINE 3 and advanced type 2 diabetes care